Literature DB >> 16984117

HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb.

Rameshwer Shukla1, Thommey P Thomas, Jennifer L Peters, Ankur M Desai, Jolanta Kukowska-Latallo, Anil K Patri, Alina Kotlyar, James R Baker.   

Abstract

In the present study, we report the synthesis and human growth factor receptor-2 (HER2) specific tumor targeting properties of a dendrimer conjugated to anti-HER2 mAb (monoclonal antibody) conjugate. The polyamidoamine (PAMAM) dendrimer generation five (G5) was labeled with alexaFluor 488 and conjugated to anti-HER2 mAb. The binding and internalization of the antibody-conjugated dendrimer to HER2-expressing cells was evaluated by flow cytometry and confocal microscopy. Uniquely, the conjugate demonstrated cellular uptake and internalization in HER2-expressing cells as compared to free antibody. The time course of internalization and blocking experiments with free antibody suggest that the rapid and efficient cellular internalization of the dendrimer-antibody conjugate was achieved without alterations in specificity of targeting. Animal studies demonstrated that the conjugate targets HER2-expressing tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16984117     DOI: 10.1021/bc050348p

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  51 in total

Review 1.  Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations.

Authors:  Wassana Wijagkanalan; Shigeru Kawakami; Mitsuru Hashida
Journal:  Pharm Res       Date:  2010-12-23       Impact factor: 4.200

2.  Design, synthesis, and biological functionality of a dendrimer-based modular drug delivery platform.

Authors:  Douglas G Mullen; Daniel Q McNerny; Ankur Desai; Xue-Min Cheng; Stassi C Dimaggio; Alina Kotlyar; Yueyang Zhong; Suyang Qin; Christopher V Kelly; Thommey P Thomas; Istvan Majoros; Bradford G Orr; James R Baker; Mark M Banaszak Holl
Journal:  Bioconjug Chem       Date:  2011-03-22       Impact factor: 4.774

3.  N-acetylgalactosamine-functionalized dendrimers as hepatic cancer cell-targeted carriers.

Authors:  Scott H Medina; Venkatesh Tekumalla; Maxim V Chevliakov; Donna S Shewach; William D Ensminger; Mohamed E H El-Sayed
Journal:  Biomaterials       Date:  2011-03-22       Impact factor: 12.479

4.  Targeting and detecting cancer cells using spontaneously formed multifunctional dendrimer-stabilized gold nanoparticles.

Authors:  Xiangyang Shi; Su He Wang; Mary E Van Antwerp; Xisui Chen; James R Baker
Journal:  Analyst       Date:  2009-04-17       Impact factor: 4.616

5.  Targeting the efficacy of a dendrimer-based nanotherapeutic in heterogeneous xenograft tumors in vivo.

Authors:  Andrzej Myc; Jolanta Kukowska-Latallo; Peter Cao; Ben Swanson; Julianna Battista; Thomas Dunham; James R Baker
Journal:  Anticancer Drugs       Date:  2010-02       Impact factor: 2.248

6.  Dendrimer-based tumor cell targeting of fibroblast growth factor-1.

Authors:  Thommey P Thomas; Rameshwer Shukla; Alina Kotlyar; Jola Kukowska-Latallo; James R Baker
Journal:  Bioorg Med Chem Lett       Date:  2009-12-03       Impact factor: 2.823

Review 7.  Nanovehicular intracellular delivery systems.

Authors:  Ales Prokop; Jeffrey M Davidson
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

8.  The effect of metal-chelating polymers (MCPs) for 111In complexed via the streptavidin-biotin system to trastuzumab Fab fragments on tumor and normal tissue distribution in mice.

Authors:  Amanda J Boyle; Peng Liu; Yijie Lu; Dirk Weinrich; Deborah A Scollard; Ghislaine Ngo Njock Mbong; Mitchell A Winnik; Raymond M Reilly
Journal:  Pharm Res       Date:  2012-08-21       Impact factor: 4.200

9.  A new application of plant virus nanoparticles as drug delivery in breast cancer.

Authors:  Neda Esfandiari; Mohsen Karimi Arzanani; Masoud Soleimani; Mina Kohi-Habibi; Winnie E Svendsen
Journal:  Tumour Biol       Date:  2015-08-19

10.  Trastuzumab labeled to high specific activity with ¹¹¹In by conjugation to G4 PAMAM dendrimers derivatized with multiple DTPA chelators exhibits increased cytotoxic potency on HER2-positive breast cancer cells.

Authors:  Conrad Chan; Zhongli Cai; Raymond M Reilly
Journal:  Pharm Res       Date:  2013-04-25       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.